CSF1R and synucleinopathy: Further investigation into the effects of CSF1R inhibitor treatment within the LPS-only treated group could yield valuable insight into whether microglial activity propels neurodegeneration, or if synucleinopathy plays a partial or intermediary role in the process of neurodegeneration.